...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Prescrire international >elotuzumab (empuciti0) combination therapy for relapsed or refractory multiple myeloma No proven therapeutic advance at this point
【24h】

elotuzumab (empuciti0) combination therapy for relapsed or refractory multiple myeloma No proven therapeutic advance at this point

机译：Elotuzumab（Empuciti0）复发或难治性多发性骨髓瘤的组合疗法在此时没有经过验证的治疗进程

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In late 2017, evaluation of elotuzumab in patients with refractory or relapsed multiple myeloma was based solely on the interim results of an unblinded clinical trial. There is no evidence that adding elotuzumab to the lenalidomide + dexamethasone combination prolongs survival. Elotuzumab can have serious adverse effects which add to those of lenalidomide, including immunosuppression. These interim results do not justify exposing patients to the adverse effects of elotuzumab. Patients with multiple myeloma often relapse after first-line treatment. There is no consensus on second-line and subsequent treatments. Options include thalidomide and lenalidomide, two immu-nosuppressive agents, or bortezomib, a 26S prote-asome inhibitor, in combination with dexametha-sone.Treatment options diminish with each relapse. When patients have already received several lines of treatment, pomalidomide, an analogue of lenalidomide and thalidomide, in combination with dexamethasone, is an option to consider if thalidomide or lenalidomide was well tolerated. The harm-benefit balance of daratumumab monotherapy, an anti-CD38 monoclonal antibody, is uncertain. Symptomatic treatment alone is also a reasonable alternative (1,2).
机译：2017年底，对耐火或复发患者的ELOTUzumab对多发性骨髓瘤的评价仅基于未结合的临床试验的中期结果。没有证据表明将Elotuzumab添加到Lenalidomide +地塞米松组合延长存活。 Elotuzumab可具有严重的不良反应，该副作用加入Lenalidomide的那些，包括免疫抑制。这些中期结果并不理由暴露于Elotuzumab的不良反应。患有多种骨髓瘤的患者经常在一线治疗后复发。二线和后续治疗没有共识。选项包括沙拉二甲胺和即苯二甲醛，两种Immu-Noosupuredive试剂，或硼替佐米，26s抗菌 - Asome抑制剂，与Dexametha-Sone.Treatment选项随着每种复发而减少。当患者已经接受了几种治疗线，氯胺，即Lenalidomide和沙利度胺的类似物，与地塞米松组合是一种选择，即考虑亚马亚度胺或番醇胺耐受良好的耐受性。达拉姆巴单疗法，抗CD38单克隆抗体的危害效益平衡是不确定的。单独的对症治疗也是合理的替代方案（1,2）。

著录项

  • 来源
    《Prescrire international》 |2018年第193期|共2页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号